RecruitingNCT06950697

Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

Sponsor

Beijing Chao Yang Hospital

Enrollment

2,400 participants

Start Date

Jan 1, 2019

Study Type

OBSERVATIONAL

Conditions

Lung Cancer Venous Thromboembolism Arterial Thromboembolism Immune Checkpoint Inhibitors (ICIs)

Summary

The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint inhibitors (ICIs) therapy. The primary questions it aims to address are: 1. What is the real-world incidence of VTE/ATE in lung cancer patients receiving immune checkpoint inhibitors? 2. What are the risk factors and biomarkers for VTE/ATE in lung cancer patients receiving immune checkpoint inhibitors? 3. What is the impact of VTE/ATE on the prognosis of lung cancer patients receiving immune checkpoint inhibitors? Researchers will compare the characteristics and biomarkers of patients with and without ICI-associated VTE/ATE to identify novel specific biomarkers for thrombotic events. Furthermore, they will construct a risk assessment model for thrombotic events to provide guidance for precision prevention and treatment in clinical practice.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is building and testing a model to predict which lung cancer patients treated with immunotherapy (immune checkpoint inhibitors) are most at risk of developing blood clots (thrombosis). It aims to improve patient monitoring and possibly prevent dangerous clotting events. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with lung cancer confirmed by a tissue biopsy or lab test - You have received at least one dose of an approved immunotherapy drug for lung cancer - You are willing to provide informed consent and comply with follow-up visits **You may NOT be eligible if...** - You do not have a confirmed lung cancer diagnosis - You are unwilling or unable to comply with the study's follow-up requirements Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.